[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Health Institutes of Turkey\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":153},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,39,58,77,92,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100650364","comparison-of-core-stability-body-awareness-pelvic-health-sleep-and-quality-of-life-in-physically-active-women-with-and-without-polyendocrine-metabolic-ovarian-syndrome-100650364",false,"NCT07747259","Comparison of Core Stability, Body Awareness, Pelvic Health, Sleep, and Quality of Life in Physically Active Women With and Without Polyendocrine Metabolic Ovarian Syndrome","Inclusion Criteria:\n\n* Being a woman aged 18-40 with a diagnosis of PMOS (n=25).\n* Being a healthy woman aged 18-40 (n=25).\n* Having practiced Pilates regularly for at least three months, at least twice a week.\n* Voluntarily agreeing to participate in the study.\n\nExclusion Criteria:\n\n* Being pregnant or in the first 6 months postpartum.\n* Being in menopause.\n* Having any other diagnosed gynecological pathology.\n* Having any significant physical limitations that would prevent the tests from being performed.\n* Having any diagnosed psychological disorder that would hinder communication.","FEMALE","18 Years","40 Years",{"count":19,"type":20},50,"ESTIMATED","OBSERVATIONAL","Aim of the study was to compare physically active women with and without Polyendocrine Metabolic Ovarian Syndrome (PMOS) in terms of core stability, body awareness, pelvic health, sleep, and quality of life, and to reveal the possible effects of the presence of PMOS on these parameters despite physical activity.",[24],"Polyendocrine Metabolic Ovarian Syndrome",[26],"Ovarian Syndrome","RECRUITING","2026-08-05",{"date":30,"type":31},"2026-08-06","ACTUAL",{"date":28,"type":31},{"date":34,"type":20},"2026-09",{"name":36,"class":37},"Health Institutes of Turkey","OTHER_GOV",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":46,"minAge":16,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":55,"completionDateStruct":56,"leadSponsor":57,"locationsCount":38},"100649826","effects-of-physical-use-characteristics-during-academic-education-on-musculoskeletal-function-and-body-awareness-in-university-students-from-different-academic-departments-100649826","NCT07739836","Effects of Physical Use Characteristics During Academic Education on Musculoskeletal Function and Body Awareness in University Students From Different Academic Departments","Inclusion Criteria:\n\n* Being a university student aged 18-25.\n* Being a second-year or higher student in the Physiotherapy and Rehabilitation Department (n=150).\n* Being a second-year or higher student in the Architecture Department (n=150).\n* Having a daily screen time (computer, tablet, mobile phone) of ≥ 3 hours.\n* Agreeing to participate in the study voluntarily.\n\nExclusion Criteria:\n\n* Having a diagnosis of surgery or serious injury in the cervical, thoracic, or lumbar region within the last 6 months.\n* Individuals with diagnosed musculoskeletal, neurological, or vestibular system pathologies.\n* Individuals with orthopedic deformities that may affect posture (e.g., scoliosis \\>20° Cobb angle).\n* Professional athletes or individuals who regularly engage in strength training.",true,"ALL","25 Years",{"count":49,"type":20},300,"Aim of the study is to compare the levels of spinal stabilization, posture, deep neck flexor muscle endurance, and body awareness of physiotherapy and rehabilitation students and architecture students, whose academic training processes and professional practices are different but intensive, and who possess different physical usage characteristics in these processes, and to reveal the effects of professional training content on the musculoskeletal system.",[52],"Physiotherapy and Rehabilitation Department Students & Architecture Department Students","2026-08-04",{"date":28,"type":31},{"date":53,"type":31},{"date":34,"type":20},{"name":36,"class":37},{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":45,"sex":64,"minAge":16,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":74,"leadSponsor":76,"locationsCount":38},"100649590","pre--and-post-training-assessment-of-sprint-performance-agility-balance-and-body-awareness-in-football-players-regarding-hamstring-injury-100649590","NCT07735416","Pre- and Post-Training Assessment of Sprint Performance, Agility, Balance and Body Awareness in Football Players Regarding Hamstring Injury","Inclusion Criteria:\n\n* Being a licensed male football player aged 18-35.\n* Having played football actively for at least 2 years.\n* Having attended training sessions regularly within the last 6 months.\n* Having a history of hamstring injury (n=25).\n* Not having a history of hamstring injury (n=25).\n* Voluntarily agreeing to participate in the study.\n\nExclusion Criteria:\n\n* Having a current history of a diagnosed musculoskeletal injury in the lower extremities.\n* Having undergone lower extremity surgery within the last 6 months.\n* Having a diagnosis of any neurological, orthopedic, or systemic disorder.\n* Having a diagnosis of any systemic disease affecting balance.\n* Having any significant physical limitations that would prevent the application of the tests.\n* Having a diagnosed psychological disorder that would hinder communication.","MALE","35 Years",{"count":19,"type":20},"Aim of the study is to examine the impact of a history of hamstring injury on athletes by determining and comparing the pre- and post-training levels of sprint performance, agility, dynamic balance, and body awareness in football players with and without a history of hamstring injury.",[69],"Hamstring Injury","2026-07-30",{"date":72,"type":31},"2026-07-31",{"date":70,"type":31},{"date":75,"type":20},"2026-08",{"name":36,"class":37},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":46,"minAge":16,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":91,"locationsCount":38},"100649548","comparison-of-upper-extremity-reaction-time-body-awareness-grip-strength-agility-and-functionality-between-wheelchair-para-armwrestling-and-para-archery-athletes-100649548","NCT07735429","Comparison of Upper Extremity Reaction Time, Body Awareness, Grip Strength, Agility and Functionality Between Wheelchair Para-Armwrestling and Para-Archery Athletes","Inclusion Criteria:\n\n* Being between 18 and 45 years of age.\n* Being a licensed wheelchair para-armwrestling athlete (n=25).\n* Being a licensed wheelchair para-archery athlete (n=25).\n* Having been regularly and actively participating in the relevant sport for at least one year.\n* Voluntarily agreeing to participate in the study.\n\nExclusion Criteria:\n\n* Having undergone surgery on the upper extremity within the last six months.\n* Having a diagnosed neurological, rheumatological, or systemic disease that may affect upper extremity function.\n* Having a diagnosed cognitive, mental, or communication disability that may negatively impact the assessment process.\n* Having a diagnosed psychological disorder that may impair communication.","45 Years",{"count":19,"type":20},"Aim of the study is to evaluate upper extremity performance between wheelchair para-armwrestling and para-archery athletes in a multidimensional way and to compare upper extremity reaction time, body awareness, grip strength, agility, and functionality parameters.",[87],"Para-Athletes",{"date":72,"type":31},{"date":70,"type":31},{"date":75,"type":20},{"name":36,"class":37},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":45,"sex":64,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":108,"leadSponsor":109,"locationsCount":38},"100648837","comparison-of-balance-core-stabilization-performance-foot-reaction-time-and-body-awareness-in-young-amateur-football-players-from-different-age-groups-100648837","NCT07726459","Comparison of Balance, Core Stabilization Performance, Foot Reaction Time and Body Awareness in Young Amateur Football Players From Different Age Groups","Inclusion Criteria:\n\n* Being a licensed amateur football player aged 13-19.\n* Having played football regularly (at least 3 days a week) for the past year.\n* Voluntarily agreeing to participate in the study.\n\nExclusion Criteria:\n\n* Having a diagnosis of any neurological, orthopedic, or systemic disorder.\n* Having a diagnosis of visual impairment or any systemic disease affecting balance.\n* Having any significant physical limitations that would prevent the administration of the tests.\n* Having a diagnosed psychological disorder that would hinder communication.","13 Years","19 Years",{"count":19,"type":20},"Aim of the study is to compare balance, core stabilization performance, foot reaction time, and body awareness in 50 amateur football players aged 13-19 (Group I: 13-15 years, and Group II: 16-19 years) according to age, and to determine age-related performance differences.",[103],"Amateur Football Players Aged 13-19","2026-07-27",{"date":106,"type":31},"2026-07-28",{"date":104,"type":31},{"date":75,"type":20},{"name":36,"class":37},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":46,"minAge":16,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":120,"phases":121,"briefSummary":124,"conditions":125,"keywords":131,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":152},"100631548","phase-2-nexcar19-talikabtagene-autoleucel-in-relapsedrefractory-b-cell-malignancies-nexcar19-100631548","NCT07502118","NexCAR19 (Talikabtagene Autoleucel) in Relapsed\u002FRefractory B-Cell Malignancies (NexCAR19)","An Open-Label, Multicenter Phase 2-3 Clinical Study of Anti-CD19 Chimeric Antigen Receptor T Cells (Talikabtagene Autoleucel) in Patients With Relapsed\u002FRefractory B-Cell Malignancies (NexCAR19)","NexCAR19","Inclusion Criteria\n\n1. All participants must meet Inclusion Criteria 1-13.\n\n   Additionally:\n2. High-grade lymphoma subjects must meet Criteria 14-18.\n3. Other B-cell lymphoma subjects must meet Criteria 19-24.\n4. B-ALL subjects must meet Criteria 25-29.\n\nGeneral Inclusion Criteria (Applicable to All Cohorts)\n\n1. Age ≥18 years.\n2. Patients approved for leukapheresis by the CAR-T cell treatment council.\n3. ECOG performance status \\\u003C2.\n4. Life expectancy ≥12 weeks.\n5. Renal Function: Estimated creatinine clearance ≥60 mL\u002Fmin (Cockcroft-Gault) → fludarabine\u002Fcyclophosphamide lymphodepletion.\n\n   In lymphoma cohort patients with creatinine clearance 30-60 mL\u002Fmin, bendamustine may be used as an alternative due to cumulative fludarabine toxicity and neurotoxicity risk.\n6. Liver Function:\n\n   1. ALT and AST ≤3 × ULN unless attributable to underlying malignancy.\n   2. Total bilirubin ≤2 × ULN except in Gilbert syndrome, isolated unconjugated hyperbilirubinemia, or if attributable to underlying malignancy.\n7. Hemodynamically stable with LVEF ≥45% (confirmed by echocardiography or MUGA scan).\n8. Baseline oxygen saturation \\>92% on room air.\n9. ANC ≥500\u002FµL (may be waived if cytopenia due to underlying malignancy at investigator discretion).\n10. Platelet count ≥50,000\u002FµL (may be waived if cytopenia due to underlying malignancy at investigator discretion).\n11. Negative serum or urine pregnancy test (within 24 hours prior to conditioning therapy) in women of childbearing potential; also negative prior to leukapheresis.\n12. Sexually active patients (women of childbearing potential and all men) must use highly effective contraception for ≥12 months after CAR-T infusion.\n13. Written informed consent provided.\n\n    High-Grade Lymphoma - Additional Inclusion Criteria (14-18)\n14. Histologically confirmed previously treated:\n\n    1. Diffuse large B-cell lymphoma (DLBCL)\n    2. Primary mediastinal B-cell lymphoma\n    3. Transformed indolent B-cell lymphoma\n    4. Follicular lymphoma Grade 3B\n    5. High-grade B-cell lymphoma\n15. Chemotherapy-refractory disease defined as:\n\n    1. Primary refractory disease\n    2. Best response to last chemotherapy = PD or SD (biopsy confirmed)\n    3. Progression\u002Frelapse ≤12 months after autologous SCT\n    4. Relapse ≤12 months after first-line CR (biopsy confirmed)\n    5. Relapse beyond 12 months if auto-SCT not feasible\n16. Not eligible for or unwilling to undergo autologous SCT.\n17. Must have received anti-CD20 monoclonal antibody and anthracycline-containing regimen. Transformed lymphoma subjects must have received ≥2 prior systemic lines.\n18. Measurable disease per International Working Group (IWG) criteria.\n\n    Other B-Cell Lymphomas - Additional Inclusion Criteria (19-24)\n19. Histologically confirmed:\n\n    1. Mantle Cell Lymphoma (Cyclin D1 overexpression or t(11;14))\n    2. Follicular Lymphoma Grade I-IIIA\n    3. Marginal Zone Lymphoma\n20. Relapsed or refractory disease:\n\n    1. MCL: ≤5 prior regimens including:\n\n       * Anthracycline or bendamustine\n       * Anti-CD20 antibody\n       * BTK inhibitor (ibrutinib or acalabrutinib; intolerance allowed)\n    2. FL\u002FMZL: Progression after ≥2 combination chemoimmunotherapy regimens (single-agent CD20 or splenectomy not counted).\n21. Radiologically measurable disease at screening\n\n    1. per revised IWG (Cheson 2007): ≥1 measurable lesion\n    2. Previously irradiated lesions measurable only if progression documented\n    3. If only nodal disease: ≥1 node ≥2 cm\n22. No known active CNS lymphoma involvement.\n23. Prior therapy toxicities resolved to ≤Grade 1 (except alopecia).\n24. Prior autologous HCT, POD24 status, and prior PI3K inhibitor therapy allowed.\n\n    B-Cell Acute Lymphoblastic Leukemia (B-ALL) - Additional Inclusion Criteria (25-29)\n25. Relapsed\u002FRefractory B-ALL meeting one of:\n\n    1. Primary refractory disease\n    2. First relapse ≤12 months\n    3. ≥2 prior systemic lines\n    4. Post-allogeneic SCT relapse (≥100 days post-transplant; off immunosuppression ≥4 weeks)\n    5. Ph+ disease:\n\n       * TKI intolerance\n       * Relapsed\u002Frefractory after ≥2 TKIs\n       * No alternative TKI option\n    6. Ineligible for allogeneic SCT due to\n\n       * comorbidity,\n       * conditioning contraindication,\n       * no donor,\n       * prior SCT,\n       * or refusal (documented).\n26. Morphological bone marrow disease.\n27. CD19 tumor expression documented within 3 months (BM or PB by flow cytometry).\n28. Absolute lymphocyte count ≥100\u002FµL.\n29. ≥3 half-lives elapsed since prior immune checkpoint inhibitor or stimulatory therapy\n\nExclusion Criteria\n\n1. All participants must meet Exclusion Criteria 1-14.\n\n   Additionally:\n2. High-grade lymphoma: 15-22\n3. Low-grade lymphoma: 23-24\n4. B-ALL: 25\n\nGeneral Exclusion Criteria (All Cohorts)\n\n1. Uncontrolled life-threatening infection (e.g., positive blood culture ≤72h before infusion).\n2. HIV positive.\n3. Active HBV replication or active HCV (RNA positive).\n4. Unstable angina or MI within 6 months.\n5. Uncontrolled cardiac arrhythmia.\n6. Concurrent malignancy except adequately treated non-melanoma skin cancer, in situ carcinoma (≥3 years disease-free), or completely resected malignancy in CR ≥3 years.\n7. Pregnant or breastfeeding.\n8. Hypersensitivity to CAR-T product excipients.\n9. Active autoimmune\u002Finflammatory neurologic disorders.\n10. Primary immunodeficiency.\n11. Short-acting leukemia\u002Flymphoma therapies must be stopped \\>72h before leukapheresis and infusion.\n12. Burkitt lymphoma\u002Fleukemia.\n13. Steroids must be discontinued \\>72h prior (\\\u003C12 mg\u002Fm²\u002Fday hydrocortisone equivalent allowed).\n14. Investigator deems subject unable to comply.\n\n    High-Grade Lymphoma - Additional Exclusion (15-22)\n15. Active CNS involvement.\n16. Prior allogeneic HSCT.\n17. Systemic immunosuppressives not discontinued ≥1 weeks before leukapheresis\u002Finfusion.\n18. Anti-proliferative therapy not stopped ≥1 weeks prior.\n19. Cytotoxic drugs not stopped ≥1 week prior.\n20. A minimum interval of ≥4 weeks is required between donor lymphocyte infusion (DLI) and leukapheresis, and ≥4 weeks between DLI and CAR-T cell infusion. This requirement applies to prior antibody-based therapies, including anti-CD20, anti-CD22, anti-CD79a, and similar agents.\n21. CNS prophylaxis not stopped \\>1 week prior.\n22. Radiation not stopped ≥2 days before leukapheresis and ≥1 week before infusion.\n\n    Low-Grade Lymphoma - Additional Exclusion (23-24)\n23. Live vaccine ≤6 weeks before conditioning.\n24. Tumor mass effect requiring urgent treatment.\n\n    B-ALL - Additional Exclusion (25)\n25. Acute graft-versus-host disease (GVHD) of Grade II-IV according to the Glucksberg criteria or Grade B-D according to the IBMTR index; or acute or chronic GVHD requiring systemic treatment within 4 weeks prior to enrollment.",{"count":119,"type":20},40,"INTERVENTIONAL",[122,123],"PHASE2","PHASE3","The NexCAR19 study is a national, open-label, multicenter Phase 2-3 clinical trial designed to evaluate the efficacy and safety of the anti-CD19 chimeric antigen receptor (CAR) T-cell product, Talikabtagene Autoleucel, in patients with relapsed\u002Frefractory B-cell malignancies, including B-cell Acute Lymphoblastic Leukemia (B-ALL) and Non-Hodgkin Lymphoma. The study is supported by the Presidency of Turkish Health Institutes (TÜSEB) and will be conducted at four centers.\n\nThis therapy is based on collecting the patient's own T cells, genetically modifying them in a laboratory to recognize the CD19 antigen, and reinfusing them into the patient. The goal is to target leukemia or lymphoma cells and achieve disease control.\n\nThe primary objective is to assess the overall response rate at Day 28 after infusion and to evaluate the safety profile of the treatment. Secondary objectives include assessment of complete response rate, duration of response, overall survival, and progression-free survival, as well as the frequency and severity of cytokine release syndrome (CRS), neurotoxicity (ICANS), and other treatment-related adverse events. In addition, the in vivo persistence and immunological effects of CAR-T cells will be evaluated.\n\nEligible patients must be 18 years of age or older, have an adequate performance status, sufficient organ function, and meet disease-specific eligibility criteria. Key exclusion criteria include active severe infection, uncontrolled cardiac disease, active central nervous system involvement (where applicable), HIV or active hepatitis infection, pregnancy, and severe immunodeficiency.\n\nThe treatment process includes leukapheresis for cell collection, administration of lymphodepleting chemotherapy if required, followed by a single infusion of CAR-T cells. Patients will be closely monitored after infusion, particularly during the early period, and both early and late adverse events, as well as treatment response, will be regularly assessed.\n\nA total of 40 patients are planned to be enrolled. The overall clinical follow-up period, including short- and long-term monitoring, is expected to last approximately 30 months. Data will be analyzed using appropriate statistical methods.",[126,127,128,129,130],"Relapsed\u002FRefractory B-cell Acute Lymphoblastic Leukemia (B-ALL)","Relapsed\u002FRefractory Non-Hodgkin Lymphoma","Diffuse Large B-Cell Lymphoma (DLBCL)","High-grade B-cell Lymphoma (HGBCL)","Follicular Lymphoma ( FL)",[132,133,134,135,136,137,138,139,140,141,142,143],"Relapsed\u002FRefractory B-Cell Malignancies","B-Cell Acute Lymphoblastic Leukemia (B-ALL)","Non-Hodgkin Lymphoma","High-Grade Lymphoma","Low-Grade Lymphoma","CD19","CAR-T Cell Therapy","Talikabtagene Autoleucel","Autologous T Cells","Adoptive Cell Therapy","Cytokine Release Syndrome (CRS)","ICANS","2026-03-24",{"date":146,"type":31},"2026-03-30",{"date":148,"type":31},"2025-09-11",{"date":150,"type":20},"2030-01-01",{"name":36,"class":37},4,""]